コンテンツへスキップ
Merck

HCYP3MAG-63K

MILLIPLEX® Human Cytokine/Chemokine Panel 3

Configurable Human Cytokine/Chemokine 11-Plex Panel 3

別名:

Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel

ログインで組織・契約価格をご覧ください。

この商品について

UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000


製品名

MILLIPLEX® Human Cytokine/Chemokine Panel 3,

description

Configurable Human Cytokine/Chemokine 11-Plex Panel 3

Quality Level

species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

assay range

accuracy: 92-106%, standard curve range: 2.0-200,000 pg/mL

technique(s)

multiplexing: suitable

input

serum
plasma
cell culture supernatant(s)

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

General description

Cytokines are versatile signaling molecules that regulate immune cell communication, inflammation, and tissue homeostasis. In metabolic and autoimmune disorders, dysregulated cytokine networks drive chronic inflammation, insulin resistance, and tissue damage. Chemokines, a subset of cytokines, direct immune cell migration to sites of injury or infection, while growth factors like M-CSF modulate cell proliferation and repair. In obesity, pro-inflammatory cytokines exacerbate adipose tissue dysfunction, whereas in autoimmune diseases, they promote aberrant immune activation against self-tissues. Conversely, anti-inflammatory cytokines work to restore equilibrium, highlighting their dual role as both drivers of pathology and potential therapeutic targets. Understanding these dynamic interactions is key to developing interventions for conditions ranging from IBD to metabolic syndrome.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 11 analytes in human serum, plasma, and cell culture supernatants.

Analytes included: GCP2, HCC-1, I-TAC, IL-11, IL-29, Lymphotactin, M-CSF, MIG, MIP-3α, MIP-3α, NAP2

Note: HCC-1/CCL14a and NAP-2/CXCL7 cannot be plexed with other analytes for serum/plasma.

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

  • Targeted Multiplex Profiling: Simultaneously quantify 11 cytokines/chemokines (e.g., MIP-3, IL-29, M-CSF) linked to metabolic disorders, obesity, and autoimmune mechanisms, enabling focused study of immune-inflammatory pathways.
  • Luminex xMAP Technology: Magnetic bead-based multiplexing ensures high sensitivity and throughput with minimal sample volume (serum, plasma, or culture supernatants).
  • Configure Your Panel: Select specific analytes (e.g., I-TAC, Lymphotactin) to tailor assays to your research needs, reducing costs and optimizing efficiency.
  • Optimized Sample Dilutions: Run most analytes neat (except NAP-2 and HCC-1, requiring 1:100 dilution for serum/plasma), simplifying workflow for diverse sample types.
  • Accelerate Translational Insights: Investigate chemokine networks in metabolic syndrome or autoimmune diseases and uncover therapeutic targets (e.g., IL-29 in viral responses, M-CSF in macrophage activation).

Legal Information

Luminex is a registered trademark of Luminex Corporation
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.


signalword

Danger

target_organs

Respiratory Tract

保管分類

10 - Combustible liquids

wgk

WGK 3

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT RE 2


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Please refer to KIT Component information

pdsc

Please refer to KIT Component information

prtr

Please refer to KIT Component information

fsl

Please refer to KIT Component information

ishl_indicated

Please refer to KIT Component information

ishl_notified

Please refer to KIT Component information

cart

キットコンポーネントの情報を参照してください

jan



試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする


関連コンテンツ

See how multiplexing the inflammation signaling pathway with MILLIPLEX® inflammation assays or cell signaling assays can help researchers bridge the gap between immunology and cell signaling, including investigating T cell signaling, Th Cell differentiation, inflammatory response signaling, and sepsis signaling.

MILLIPPLEX®炎症アッセイまたは細胞シグナル伝達アッセイを用いた炎症シグナル伝達経路のマルチプレックス測定が、T細胞シグナル伝達、Th細胞分化、炎症反応シグナル伝達、敗血症シグナル伝達の研究など、免疫学と細胞シグナル伝達の間のギャップを埋めるためにどのように役立っているのかをご覧ください。

すべての関連コンテンツを見る

Kristen M Reeder et al.
Mucosal immunology, 11(5), 1352-1362 (2018-06-17)
Asthmatics sensitized to fungi are reported to have more severe asthma, yet the immunopathogenic pathways contributing to this severity have not been identified. In a pilot assessment of human asthmatics, those subjects sensitized to fungi demonstrated elevated levels of the
Marie L Landry et al.
The Journal of infectious diseases, 217(6), 897-905 (2017-12-28)
Despite the high burden of respiratory infection and the importance of early and accurate diagnosis, there is no simple diagnostic test to rule in viral infection as a cause of respiratory symptoms. We performed RNA sequencing on human nasal epithelial
Alice L den Hertog et al.
PloS one, 10(6), e0129552-e0129552 (2015-06-27)
Many patients treated for tuberculosis (TB) in low and middle income countries are treated based on clinical suspicion without bacteriological confirmation. This is often due to lack of rapid simple accurate diagnostics and low healthcare provider confidence in the predictive